The landscape of therapeutics for Niemann-Pick Disease Type C (NPC) is a evolving one, with considerable strides being made in research. Several promising therapeutic approaches are currently experiencing pre-clinical evaluation, offering optimism for sufferers living with this rare and progressive brain-related disorder. A combination of pharmaco